nirmatrelvir / ritonavir (Paxlovid) for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 outpatients meta-analysis
EPIC-HR NCT04960202		RCT	nirmatrelvir / ritonavir (Paxlovid)	placebo	COVID 19 outpatients	low	1120/1126	conclusif	demonstrated 88 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias suggested 96 % decrease in deaths,death D28 with a high degree of certainty due to low risk of bias statistically significant 76 % increase in related AE (TRAE) with a high degree of certainty due to low risk of bias Based on laboratory studies only, Paxlovid is also expected to be active against Omicron and other variants.

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 outpatients meta-analysis